Compare Ascendis Pharma A/S (ASND) vs M&T Bank Corporation (MTB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs M&T Bank Corporation — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while M&T Bank Corporation trades at $242.34 (market cap $35.49B). The key difference: M&T Bank Corporation is far larger — about 2× Ascendis Pharma A/S's market cap, and M&T Bank Corporation pays a 2.48% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MTB | |
|---|---|---|
Market Cap | $17.74B | $35.49B |
Sector | Health | Financials |
52-Week High | $277.18 | $242.34 |
52-Week Low | $163.32 | $178.63 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
M&T Bank (MTB) trades at $242.34, up 1.85% with a bullish technical signal. The stock shows consistent earnings beats with Q1 2026 EPS of $4.18 exceeding expectations. Fundamentals remain solid with a P/E of 13.61 and net income margin of 30.11%. Recent corporate actions include a $1.50 dividend payment scheduled for June 2026 and new board appointments supporting growth initiatives.
MTB presents a balanced investment case with strong profitability metrics and analyst consensus near current levels. The upcoming Q2 2026 earnings report on July 15 represents a key catalyst. Risks include negative cash flow trends and potential interest rate sensitivity. Institutional sentiment leans cautious with 62.5% hold ratings, suggesting measured optimism for the regional banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
